DE
MRNA icon

DV Equities’s Moderna MRNA Stock Holding History

DV Equities’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$14.3K Buy
+485
New +$13.2K ﹤0.01% 592

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

DV Equities's MRNA Position: Q4 2025 in Review

DV Equities opened a new position in Moderna (MRNA) in Q4 2025: 485 shares worth $14.3K. The stake represents ﹤0.01% of the portfolio and ranks #592 among its holdings.

675 funds tracked by Wall St. Rank hold MRNA as of Q4 2025.

  • DV Equities held 485 shares of Moderna worth $14.3K as of Q4 2025.
  • Moderna was a new DV Equities position in Q4 2025.
  • Moderna made up ﹤0.01% of DV Equities's portfolio in Q4 2025, its #592 holding.
  • 675 funds tracked by Wall St. Rank held Moderna as of Q4 2025.

Based on DV Equities's 13F filing for Q4 2025, filed 17 Feb 2026.